Primary care providers can use a new clinical advisory guideline to nutritionally support patients who are using GLP-1 ...

A doctor has spoken about their own '100-year-old rule' they have when it comes to things like taking Ozempic.

The medication initially helped get his type 2 diabetes into remission, and enjoy active social excursions that he couldn't ...

The report also underscored the importance of maintaining muscle mass and bone density while losing weight. Since weight loss ...

Novo Nordisk (NYSE: NVO) and Cava Group (NYSE: CAVA) are excellent choices. Novo Nordisk's shares have significantly lagged ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes ...

Compounded GLP-1s are no longer to be sold following the FDA announcement that the shortage of semaglutide and tirzepatide ended.

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Q2 2025 Earnings Call Transcript May 28, 2025 Agilent Technologies, Inc. beats earnings expectations. Reported EPS is $1.31, ...

When Michael Donnelly-Boylen was diagnosed with type 2 diabetes, he knew he had to "fight" to lose weight. Starting Mounjaro ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.